|
|
Current and Breaking News for Professionals, Consumers and Media |
|
|
|
|
|
|
| Current and Breaking News for Professionals, Consumers and Media |
|
|
|
|
|
“It’s easy to recognize a problem in healthcare, yet creating a safe and effective solution to that problem may take years of dedicated effort from a variety of highly trained professionals,” says Terry Herring, President of Commercial Operations at Mission Pharmacal Company. “When we received commercialization rights to distribute BINOSTO in the United States, we were especially grateful for the expertise and guidance we received from Dr. Sol Epstein, an international expert in osteoporosis and bone health.” Sol Epstein, MD, FRCP, FACP, is professor of Medicine and Geriatrics at Mt. Sinai University School of Medicine and a fellow of the American College of Physicians and the Royal College of Physicians. In addition to his role as a professor, Dr. Epstein continues to perform basic research at Mt. Sinai. He has focused most of his medical career on osteoporosis and bone disease, and has more than 250 peer-reviewed publications and multiple text book chapters to his credit. Dr. Epstein is concerned that neither physicians nor patients appreciate the morbidity and mortality risks associated with this very common disease. “Each year there are about 1.5 million osteoporotic fractures, more than the number of heart attacks or breast cancer diagnoses,” says Epstein. “Yet the number is actually higher, since many spinal fractures aren’t discovered unless the patient happens to have a chest X-ray. This is a crisis because once a patient has had a fracture, the risk for subsequent fractures and early death is increased by as much as four times.” In addition to the human toll, Epstein says it’s important to understand the financial burden caused by osteoporosis. “In the United States, we are spending about $20 billion a year treating osteoporotic hip fractures, and that cost is rising quickly. With early diagnosis and treatment, many fractures can be prevented,” he asserts. “Alendronate sodium (the active ingredient in BINOSTO) is the first drug to show significant fracture reduction at all sites over the long term. It’s vital that doctors talk to their patients about their risks for osteoporosis and how to prevent fractures,” Epstein advises. Now that alendronate sodium is available in an easy-to-swallow buffered solution, Dr. Epstein recommends that physicians also ask whether their patients are among the millions who have difficulty swallowing tablets or pills. “BINOSTO provides a great alternative for patients who prefer not to or struggle to take pills.” For anyone with osteoporosis, the best protection against falling victim to a life-threatening fracture is taking medications as prescribed by an authorized healthcare provider. However, studies show that people who have trouble swallowing pills are much more likely to stop taking their medication. Taken just once a week, strawberry flavored BINOSTO in a buffered effervescent solution may improve long-term patient compliance, thus decreasing the risks of disabling fractures. About BINOSTO BINOSTO is a once weekly, strawberry flavored effervescent tablet containing alendronate sodium (70mg) that rapidly dissolves in half a glass (4 oz.) of plain room temperature water to make a buffered solution. BINOSTO is available in cartons containing four individual tablets. The national drug code number is 0178-0101-02. BINOSTO was developed by EffRx based on an agreement with Merck & Co, Inc. granting EffRx the worldwide rights to all effervescent and related patents of FOSAMAXâ (alendronate). Patents have been granted to EffRx providing exclusivity for BINOSTO through February 2023. Additional patents are pending. About Mission Pharmacal Company Mission Pharmacal Company is a privately held pharmaceutical company based in San Antonio, Texas. For more than 65 years, the company has been committed to meeting the unique healthcare needs of women throughout all stages of life, pediatric patients, and those persons dealing with urologic and dermatologic conditions. The company has a proven track record of identifying unmet healthcare needs and developing both innovative prescription and over-the-counter products to meet these needs. Using only the purest ingredients, Mission Pharmacal provides physicians and consumers with the highest quality pharmaceutical and dietary supplement products on the market today. Mission Pharmacal is a proud national supporter of the March of Dimes Foundation, whose mission is to improve the health of babies by preventing birth defects, premature birth, and infant mortality. For more information about the company, visit www.missionpharmacal.com. ### For advertising and promotion on HealthNewsDigest.com please contact Mike McCurdy: tvmike13@HealthNewsDigest.com or 877-634-9180 HealthNewsDigest.com is syndicated worldwide, to thousands of journalists in all media, and health-related websites. www.HealthNewsDigest.com Top of Page 
|
Contact
Us | Job Listings
| Help | Site
Map | About Us
Advertising
Information | HND
Press Release | Submit
Information | Disclaimer
Site hosted by Sanchez Productions
